HEATHER LYNN MCARTHUR

Medical Oncology

Professional Links

KOL Overview:

Total Payments 2017-2023 to Dr.HEATHER LYNN MCARTHUR: $237,046

Company	Total	2017	2018	2019	2020	2021	2022	2023
Merck Sharp & Dohme LLC	$44,749	$0	$0	$0	$0	$0	$6,528	$38,221
Merck Sharp & Dohme Corporation	$39,097	$10,645	$5,505	$7,131	$5,817	$10,000	$0	$0
Lilly USA, LLC	$34,715	$29,308	$3,133	$0	$2,275	$0	$0	$0
AstraZeneca Pharmaceuticals LP	$22,792	$621	$552	$1,830	$0	$2,740	$12,461	$4,588
Seagen Inc.	$15,786	$0	$0	$0	$11,037	$2,760	$0	$1,990

Source: OpenPaymentsData.CMS.gov

Top Tweets

Great to see you @GWerutsky at #SABCS23 and excited to have Brazil join the exciting #TROPIONBreast04 effort! Such an important study!! https://t.co/RGCbWWsDL0

@TumorBoardTues @prarthnavb @PTarantinoMD @Dr_RShatsky @ErikaHamilton9 @CharuAggarwalMD @dradityabardia @hoperugo @maryam_lustberg @drteplinsky @DrSGraff @jane_meisel BTW, its coke all the way!! :)

@prarthnavb @TumorBoardTues @MPishvaian @JohnEbbenMDPhD @YAbdouMD @PTarantinoMD @drteplinsky @ArielleMedford @stolaney1 @nlinmd @dradityabardia @hoperugo @maryam_lustberg @Dr_RShatsky @ErikaHamilton9 @BCJoyceO @DrGattiMays @laura_huppert @drivorymd @DrSGraff @jane_meisel @JenniferLitton @drsarahsam @IlanaSchlam ki67 should never have been included in the original approval in my mind! Glad they made the change to high risk, node-pos!

@JohnEbbenMDPhD @prarthnavb @TumorBoardTues @MPishvaian @YAbdouMD @PTarantinoMD @drteplinsky @ArielleMedford @stolaney1 @nlinmd @dradityabardia @hoperugo @maryam_lustberg @Dr_RShatsky @ErikaHamilton9 @BCJoyceO @DrGattiMays @laura_huppert @drivorymd @DrSGraff @jane_meisel @JenniferLitton @drsarahsam @IlanaSchlam Adjuvant abema is currently approved in patients with high risk node-pos disease. Benefits from MonarchE study were consistent across all subgroups interrogated.